FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027242209> ?p ?o ?g. }

• W2027242209 endingPage "351" @default.
• W2027242209 startingPage "346" @default.
• W2027242209 abstract "Development of acquired resistance limits the utility of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for the treatment of EGFR-mutant lung cancers. There are no accepted targeted therapies for use after acquired resistance develops. Metastasectomy is used in other cancers to manage oligometastatic disease. We hypothesized that local therapy is associated with improved outcomes in patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKI.Patients who received non-central nervous system local therapy were identified by a review of data from a prospective biopsy protocol for patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKI therapy and other institutional biospecimen registry protocols.Eighteen patients were identified, who received elective local therapy (surgical resection, radiofrequency ablation, or radiation). Local therapy was well tolerated, with 85% of patients restarting TKI therapy within 1 month of local therapy. The median time to progression after local therapy was 10 months (95% confidence interval [CI]: 2-27 months). The median time until a subsequent change in systemic therapy was 22 months (95% CI: 6-30 months). The median overall survival from local therapy was 41 months (95% CI: 26-not reached).EGFR-mutant lung cancers with acquired resistance to EGFR TKI therapy are amenable to local therapy to treat oligometastatic disease when used in conjunction with continued EGFR inhibition. Local therapy followed by continued treatment with an EGFR TKI is well tolerated and associated with long PFS and OS. Further study in selected individuals in the context of other systemic options is required." @default.
• W2027242209 created "2016-06-24" @default.
• W2027242209 creator A5001058762 @default.
• W2027242209 creator A5008675566 @default.
• W2027242209 creator A5014837967 @default.
• W2027242209 creator A5029855909 @default.
• W2027242209 creator A5035120516 @default.
• W2027242209 creator A5039791495 @default.
• W2027242209 creator A5042405172 @default.
• W2027242209 creator A5050489521 @default.
• W2027242209 creator A5052336062 @default.
• W2027242209 creator A5052930984 @default.
• W2027242209 creator A5060033755 @default.
• W2027242209 creator A5068743826 @default.
• W2027242209 creator A5075877134 @default.
• W2027242209 date "2013-03-01" @default.
• W2027242209 modified "2023-10-14" @default.
• W2027242209 title "Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors" @default.
• W2027242209 cites W1980497534 @default.
• W2027242209 cites W1981083257 @default.
• W2027242209 cites W1986070056 @default.
• W2027242209 cites W1988939419 @default.
• W2027242209 cites W1989188414 @default.
• W2027242209 cites W1995092114 @default.
• W2027242209 cites W1998971866 @default.
• W2027242209 cites W2003904380 @default.
• W2027242209 cites W2003984225 @default.
• W2027242209 cites W2031343278 @default.
• W2027242209 cites W2043696829 @default.
• W2027242209 cites W2048004755 @default.
• W2027242209 cites W2055402151 @default.
• W2027242209 cites W2061935522 @default.
• W2027242209 cites W2074113942 @default.
• W2027242209 cites W2080189021 @default.
• W2027242209 cites W2093613683 @default.
• W2027242209 cites W2110090013 @default.
• W2027242209 cites W2111662961 @default.
• W2027242209 cites W2112689533 @default.
• W2027242209 cites W2114403047 @default.
• W2027242209 cites W2128208856 @default.
• W2027242209 cites W2128928659 @default.
• W2027242209 cites W2129360604 @default.
• W2027242209 cites W2132157071 @default.
• W2027242209 cites W2138089710 @default.
• W2027242209 cites W2139236349 @default.
• W2027242209 cites W2145835533 @default.
• W2027242209 cites W2145980885 @default.
• W2027242209 cites W2150575159 @default.
• W2027242209 cites W2160336497 @default.
• W2027242209 cites W2161821474 @default.
• W2027242209 cites W2162394887 @default.
• W2027242209 cites W2166084034 @default.
• W2027242209 cites W2168691181 @default.
• W2027242209 doi "https://doi.org/10.1097/jto.0b013e31827e1f83" @default.
• W2027242209 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3673295" @default.
• W2027242209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23407558" @default.
• W2027242209 hasPublicationYear "2013" @default.
• W2027242209 type Work @default.
• W2027242209 sameAs 2027242209 @default.
• W2027242209 citedByCount "285" @default.
• W2027242209 countsByYear W20272422092013 @default.
• W2027242209 countsByYear W20272422092014 @default.
• W2027242209 countsByYear W20272422092015 @default.
• W2027242209 countsByYear W20272422092016 @default.
• W2027242209 countsByYear W20272422092017 @default.
• W2027242209 countsByYear W20272422092018 @default.
• W2027242209 countsByYear W20272422092019 @default.
• W2027242209 countsByYear W20272422092020 @default.
• W2027242209 countsByYear W20272422092021 @default.
• W2027242209 countsByYear W20272422092022 @default.
• W2027242209 countsByYear W20272422092023 @default.
• W2027242209 crossrefType "journal-article" @default.
• W2027242209 hasAuthorship W2027242209A5001058762 @default.
• W2027242209 hasAuthorship W2027242209A5008675566 @default.
• W2027242209 hasAuthorship W2027242209A5014837967 @default.
• W2027242209 hasAuthorship W2027242209A5029855909 @default.
• W2027242209 hasAuthorship W2027242209A5035120516 @default.
• W2027242209 hasAuthorship W2027242209A5039791495 @default.
• W2027242209 hasAuthorship W2027242209A5042405172 @default.
• W2027242209 hasAuthorship W2027242209A5050489521 @default.
• W2027242209 hasAuthorship W2027242209A5052336062 @default.
• W2027242209 hasAuthorship W2027242209A5052930984 @default.
• W2027242209 hasAuthorship W2027242209A5060033755 @default.
• W2027242209 hasAuthorship W2027242209A5068743826 @default.
• W2027242209 hasAuthorship W2027242209A5075877134 @default.
• W2027242209 hasBestOaLocation W20272422091 @default.
• W2027242209 hasConcept C121608353 @default.
• W2027242209 hasConcept C126322002 @default.
• W2027242209 hasConcept C143998085 @default.
• W2027242209 hasConcept C170493617 @default.
• W2027242209 hasConcept C185926286 @default.
• W2027242209 hasConcept C2776256026 @default.
• W2027242209 hasConcept C2776999253 @default.
• W2027242209 hasConcept C2777506169 @default.
• W2027242209 hasConcept C2778820342 @default.
• W2027242209 hasConcept C2779438470 @default.
• W2027242209 hasConcept C2780580887 @default.
• W2027242209 hasConcept C2780586478 @default.

• next